In this study, we used an in vivo mouse model of lung cancer i.e., EGFRL858R mice, in which lung cancer is induced by doxycycline treatment, to establish an animal model of drug resistance by long-term treatment with 20 mg/kg gefitinib, an EGFR tyrosine kinase inhibitor (TKI). Here, EGFR is linked to lung carcinoma.